COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01083615
Recruitment Status : Terminated (Unable to enroll due to criteria for stable baseline pain)
First Posted : March 10, 2010
Last Update Posted : October 12, 2016
Teva Pharmaceuticals USA
Information provided by (Responsible Party):
Achieve Life Sciences

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : March 2013
Actual Study Completion Date : March 2013
Certification/Extension First Submitted : November 4, 2015